ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 131 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is 0.83 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $2,849,000 | +47.4% | 85,043 | +17.1% | 0.00% | +50.0% |
Q3 2016 | $1,933,000 | +20.9% | 72,626 | +0.1% | 0.00% | 0.0% |
Q2 2016 | $1,599,000 | -14.5% | 72,530 | +13.9% | 0.00% | 0.0% |
Q1 2016 | $1,871,000 | -9.3% | 63,694 | +1.9% | 0.00% | -33.3% |
Q4 2015 | $2,063,000 | -8.4% | 62,485 | +0.3% | 0.00% | 0.0% |
Q3 2015 | $2,252,000 | -11.9% | 62,314 | +9.7% | 0.00% | 0.0% |
Q2 2015 | $2,556,000 | +175.1% | 56,809 | +87.2% | 0.00% | +200.0% |
Q1 2015 | $929,000 | -39.0% | 30,342 | +1.2% | 0.00% | -50.0% |
Q4 2014 | $1,524,000 | +28.2% | 29,979 | -0.3% | 0.00% | 0.0% |
Q3 2014 | $1,189,000 | -7.7% | 30,057 | +0.5% | 0.00% | 0.0% |
Q2 2014 | $1,288,000 | +211.9% | 29,914 | +189.7% | 0.00% | +100.0% |
Q1 2014 | $413,000 | +49.6% | 10,326 | +2.1% | 0.00% | – |
Q4 2013 | $276,000 | +19.0% | 10,118 | -0.0% | 0.00% | – |
Q3 2013 | $232,000 | +44.1% | 10,123 | +11.4% | 0.00% | – |
Q2 2013 | $161,000 | – | 9,088 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Krensavage Asset Management, LLC | 936,777 | $53,218,000 | 16.69% |
Fairmount Funds Management LLC | 316,952 | $18,006,000 | 6.55% |
ARMISTICE CAPITAL, LLC | 1,836,000 | $104,303,000 | 1.77% |
Soleus Capital Management, L.P. | 182,400 | $10,362,000 | 1.62% |
Portland Global Advisors LLC | 62,635 | $3,558,000 | 0.66% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 40,000 | $2,263,000 | 0.55% |
FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $113,336,000 | 0.53% |
Yorktown Management & Research Co Inc | 10,400 | $591,000 | 0.44% |
Hennion & Walsh Asset Management, Inc. | 120,240 | $6,831,000 | 0.36% |
Virtus ETF Advisers LLC | 9,599 | $545,000 | 0.24% |